Design, docking study and ADME prediction of Isatin derivatives as anti-HIV agents

Pawar, Vidya; Lokwani, Deepak K.; Bhandari, Shashikant V.; Bothara, Kailash G.; Chitre, Trupti S.; Devale, Titiksh L.; Modhave, Nileema S.; Parikh, Jignesh

doi:10.1007/s00044-010-9329-y

Cited by 30 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isatin derivatives revealed a fascinating array of pharmacological activities, such as anticancer [ 10 ], anti-HIV [ 11 ], antiviral [ 12 ], antitumor [ 13 ], antifungal [ 14 ], antimalarial [ 15 ], antioxidant [ 16 ], anti-inflammatory [ 17 ], antimicrobial [ 18 ], analgesic [ 19 ], anticonvulsants [ 20 ], and so on. Several conventional analogues of isatin are currently being used for medicinal purposes, and some representative examples of marketed drugs containing isatin scaffolds against multiple diseases/disorders are displayed in Figure 2 .…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery

Cheke¹,

Patil²,

Firke

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

Isatin (1H indole 2, 3-dione) is a heterocyclic, endogenous lead molecule recognized in humans and different plants. The isatin nucleus and its derivatives are owed the attention of researchers due to their diverse pharmacological activities such as anticancer, anti-TB, antifungal, antimicrobial, antioxidant, anti-inflammatory, anticonvulsant, anti-HIV, and so on. Many research chemists take advantage of the gentle structure of isatins, such as NH at position 1 and carbonyl functions at positions 2 and 3, for designing biologically active analogues via different approaches. Literature surveys based on reported preclinical, clinical, and patented details confirm the multitarget profile of isatin analogues and thus their importance in the field of medicinal chemistry as a potent chemotherapeutic agent. This review represents the recent development of isatin analogues possessing potential pharmacological action in the years 2016–2020. The structure–activity relationship is also discussed to provide a pharmacophoric pattern that may contribute in the future to the design and synthesis of potent and less toxic therapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery

Cheke¹,

Patil²,

Firke

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…From 2D and 3D interaction diagrams of elvitegravir (Table 4, Figure 5), it was found that standard inhibitor binds to the target site; showed hydrogen bonding interaction with LYS 101, ILE-180, and LEU-100 and docking score (-8.57). The standard drug rilpivirine also showed hydrogen bonding with LYS 101; its docking score was -8.56 (literature value = -7.61) [33]. The designed compounds fit best in the allosteric site of HIV reverse transcriptase.…”

Section: Molecular Docking Studiesmentioning

confidence: 93%

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors

et al. 2020

View full text Add to dashboard Cite

It has been over three decades since HIV, the causative agent for acquired immunodeficiency syndrome (AIDS), was identified. From the beginning of the global pandemic of HIV in the early 1980s, an estimated 78 million people have been infected with HIV; about 39 million people have died of AIDS-related causes [1]. There are 2 major types of HIV, HIV-1 and HIV-2, out of which HIV-1 is the more virulent and pathogenic. HIV reverse transcriptase enzyme specifically synthesizes double-stranded DNA from single-stranded viral RNA and is an important target for anti-HIV drug development. In the early 1990s, potent HIV reverse transcriptase inhibitors (RTIs) with significant clinical activity were developed. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are leading drugs in the treatment of HIV-1 infections [2]. NNRTIs are capable of reducing the viral reservoirs in the brain due to their high lipophilicity because of the absence of sugar molecules in their structure. Currently, highly active antiretroviral therapy (HAART) combination therapy is used for the treatment of HIV to avoid the development of resistance against a single drug, but it also causes psychiatric and neurological side effects [3]. Hence, there is a dire need for novel anti-HIV agents with fewer side effects. Drug discovery is a very long and costly procedure. It requires 10-15 years and billions of dollars to discover a new drug. CADD tools significantly reduce time and monetary investment in drug discovery. Molecular docking is one of the most important tools of CADD used in drug discovery today to understand drug-receptor interactions, the binding affinity of drugs, and orientation of drug molecules to the target site. This helps in better prediction of activity and reduction in side effects, and is a rational approach to drug design [4]. Quinoline and pyrimidine are important scaffolds for anti-HIV drugs. Hameed et al. designed and synthesized quinoline-based chalcones as HIV reverse transcriptase (RT) inhibitors. Molecular docking studies were performed for the synthesized compounds to determine their binding affinity in the active site of the enzyme. HIV-RT bioassay was used Abstract: Quinoline moiety is an important scaffold in the field of drug discovery and drug development, with a wide range of pharmacological activities. Quinoline derivatives are potent inhibitors for reverse transcriptase, which is responsible for the conversion of single-stranded viral RNA into double-stranded viral DNA.In the present study, we have designed and synthesized 2 series, namely pyrazoline and pyrimidine containing quinoline derivatives as non nucleoside reverse transcriptase inhibitors (NNRTIs). Eleven compounds were synthesized and characterized by 1 H and 13 C NMR and mass spectrophotometry. The synthesized compounds were also docked on an HIV reverse transcriptase binding site (PDB: 4I2P); most of these compounds showed good binding interactions with the active domain of the receptor. Most of the compounds displayed a docking score higher than tho...

show abstract

“…In their quest to develop new anti-HIV therapeutics, Pawar et al [ 45 ] designed various isatin analogs [ 14 ] (Fig. 16 ).…”

Section: Isatin Derivatives As Anti-hiv Agentsmentioning

confidence: 99%

Isatin derivatives as broad-spectrum antiviral agents: the current landscape

et al. 2022

View full text Add to dashboard Cite

In recent decades, several viruses have resulted in large outbreaks with serious health, economic and social consequences. The current unprecedented outbreak of the new coronavirus, SARS-COV-2, necessitates intensive efforts for delivering effective therapies to eradicate such a deadly virus. Isatin is an opulent heterocycle that has been proven to provide tremendous opportunities in the area of drug discovery. Over the last fifty years, suitably functionalized isatin has shown remarkable and broad-spectrum antiviral properties. The review herein is an attempt to compile all of the reported information about the antiviral activity of isatin derivatives with an emphasis on their structure-activity relationships (SARs) along with mechanistic and molecular modeling studies. In this regard, we are confident that the review will afford the scientific community a valuable platform to generate more potent and cost-effective antiviral therapies based on isatin templates.

show abstract

Design, docking study and ADME prediction of Isatin derivatives as anti-HIV agents

Cited by 30 publications

References 21 publications

Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery

Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors

Isatin derivatives as broad-spectrum antiviral agents: the current landscape

Contact Info

Product

Resources

About